NESS ZIONA, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced that that the Company will present at the upcoming H.C. Wainwright Global Investment Conference being held May 23-26, 2022.
||H.C. Wainwright Global Investment Conference
||May 23-26 2022
||On-demand presentation and 1:1 meetings
||Presentation available on-demand beginning Tuesday, May 24th at 7:00 am Eastern Daylight Time
About Sol-Gel Technologies
Sol-Gel is a dermatology company focused on identifying, developing and commercializing or partnering branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leveraged its proprietary microencapsulation technology platform for TWYNEO®, which is approved for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, which is approved for the treatment of inflammatory lesions of rosacea in adults. Both drugs are exclusively licensed to Galderma for U.S. commercialization.
The Company’s pipeline also includes early-stage topical drug candidates SGT-210, SGT-310 and SGT-510 under investigation for the treatment of plaque psoriasis and other dermatologic indications.
For further information, please contact:
Investor relations, LifeSci Advisors
+1 917 734 7387
Chief Financial Officer
Source: Sol-Gel Technologies Ltd.